Listen
OXYCONTIN - OXYNORM - OXYNORMORO
Reason for request
-
Clinical Benefit
| Insufficient |
the actual benefit of these proprietary medicinal products in comparison with the treatments that are already available for this type of pain is not sufficient to justify reimbursement by National Health Insurance |
| Substantial |
The actual benefit of these proprietary medicinal products remains substantial in the treatment of cancer-related pain, which can be adequately managed only by opioid analgesics. The actual benefit of these proprietary medicinal products is substantial in the treatment of non-cancer-related pain. The actual benefit of these proprietary medicinal products is substantial in the treatment of neuropathic pain. |
Clinical Added Value
| no clinical added value |
OXYCONTIN, OXYNORM and OXYNORMORO do not provide an improvement in actual benefit (IAB V) in comparison with immediate- and prolonged-release morphine-based products in the management of severe cancer-related, post-operative and neuropathic pain. |
